FCMV
XENE icon

Foresite Capital Management VI’s Xenon Pharmaceuticals XENE Stock Holding History

Foresite Capital Management VI’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-160,000
Closed -$5.01M – 20
2025
Q2 		$5.01M Buy
+160,000
New +$5.22M 2.82% 12

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Foresite Capital Management VI's XENE Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 160,000 shares — an estimated $5.01M sold.

Foresite Capital Management VI first reported a position in XENE in Q2 2025 and held it in 1 quarter. The position peaked at $5.01M in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 160,000 Xenon Pharmaceuticals shares in Q3 2025, an estimated $5.01M.
  • Foresite Capital Management VI first reported a position in Xenon Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Foresite Capital Management VI's Xenon Pharmaceuticals position peaked at $5.01M in Q2 2025.
  • 219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.